Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: A very long term comparative study and literature review

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Parisi, Salvatore ^a   Corsa, Pietro ^a   Raguso, Arcangela ^a   Perrone, Antonio ^a   Cossa, Sabrina ^a   Munafò, Tindara ^a   Sanpaolo, Gerardo ^a   Donno, Elisa ^a   Clemente, Maria Antonietta ^a   Piombino, Michele ^b   Parisi, Federico ^c   Valle, Guido ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b POLICLINICO   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; CORTICOSTEROID; FOTEMUSTINE; GRANISETRON; ONDANSETRON; TEMOZOLOMIDE; DACARBAZINE;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; BRAIN HISTOLOGY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KARNOFSKY PERFORMANCE STATUS; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEREOTACTIC BIOPSY; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; GLIOMA; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84925340751     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/620643     Document Type: Article

References (50)

1. L. M. DeAngelis, P. C. Burger, S. B. Green, and J. G. Cairncross, "Malignant glioma: who benefits from adjuvant chemotherapy" Annals of Neurology, vol. 44, no. 4, pp. 691-695, 1998.
2. E. Galanis and J. Buckner, "Chemotherapy for high-grade gliomas, " British Journal of Cancer, vol. 82, no. 8, pp. 1371-1380, 2000.
3. J. Del Rowe, C. Scott, M. Werner-Wasik et al., "Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme, " Journal of Clinical Oncology, vol. 18, no. 6, pp. 1254-1259, 2000.
4. H. A. Fine, K. B. G. Dear, J. S. Loeffler, P. M. Black, and G. P. Canellos, "Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults, " Cancer, vol. 71, no. 8, pp. 2585-2597, 1993.
5. B. J. Fisher, C. Scott, D. R. Macdonald, C. Coughlin, and W. J. Curran, "Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group trial 9507, " Journal of Clinical Oncology, vol. 19, no. 4, pp. 1111-1117, 2001.
6. D. Thomas, M. Brada, S. Stenning et al., "Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council Trial, " Journal of Clinical Oncology, vol. 19, no. 2, pp. 509-518, 2001.
7. Glioma Meta-Analysis Trialist (GMT) Group, "Chemotherapy in adult high-grade glioma: a systematic review and metaanalysis of individual patient data from 12 randomised trials, " The Lancet, vol. 359, no. 9311, pp. 1011-1018, 2002.
8. R. Stupp, M. Gander, S. Leyvraz, and E. Newlands, "Current and future developments in the use of temozolomide for the treatment of brain tumours, " The Lancet Oncology, vol. 2, no. 9, pp. 552-560, 2001.
9. P. Corsa, S. Parisi, M. Piombino et al., "A preliminary retrospective study with temozolomide and radiotherapy versus radiotherapy alone for the treatment of high-grade gliomas, " International Journal of Radiation Oncology, Biology, Physics, vol. 57, supplement 2, p. S378, 2003.
10. E. P. M. Jansen, L. G. H. Dewit, M. VanHerk, and H. Bartelink, "Target volumes in radiotherapy for high-grade malignant glioma of the brain, " Radiotherapy and Oncology, vol. 56, no. 2, pp. 151-156, 2000.
11. A. P. Andersen, "Postoperative irradiation of glioblastomas. Results in a randomized series, " Acta Radiologica: Oncology, vol. 17, pp. 474-484, 1978.
12. K. Kristiansen, S. Hagen, T. Kollevold et al., "Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group, " Cancer, vol. 47, no. 4, pp. 649-652, 1981.
13. W. R. Shapiro and D. F. Young, "Treatment ofmalignant glioma. A controlled study of chemotherapy and irradiation, " Archives of Neurology, vol. 33, no. 7, pp. 494-500, 1976.
14. M. D. Walker, E. Alexander Jr., W. E. Hunt et al., "Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial, " Journal of Neurosurgery, vol. 49, no. 3, pp. 333-343, 1978.
15. J. Van Rijn, J. J. Heimans, J. Van Den Berg, P. Van Der Valk, and B. J. Slotman, "Survival of human glioma cells treated with various combination of temozolomide and X-rays, " International Journal of Radiation Oncology Biology Physics, vol. 47, no. 3, pp. 779-784, 2000.
16. M. Brada, K. Hoang-Xuan, R. Rampling et al., "Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, " Annals of Oncology, vol. 12, no. 2, pp. 259-266, 2001.
17. S. M. Chang, K. R. Lamborn, M. Malec et al., "Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme, " International Journal of Radiation Oncology, Biology, Physics, vol. 60, no. 2, pp. 353-357, 2004.
18. O. L. Chinot, S. Honore, H. Dufour et al., "Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy, " Journal of Clinical Oncology, vol. 19, no. 9, pp. 2449-2455, 2001.
19. H. S. Friedman, R. E. McLendon, T. Kerby et al., "DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosedmalignant glioma, " Journal of Clinical Oncology, vol. 16, no. 12, pp. 3851-3857, 1998.
20. M. Gilbert, J. Olson, and W. Yung, "Preradiation treatment of newly diagnosed anaplastic astrocytomas and glioblastomamultiforme using temozolomide, " Neuro-Oncology, vol. 2, abstract 77, p. 264, 2000.
21. E. S. Newlands, M. F. G. Stevens, S. R. Wedge, R. T. Wheelhouse, and C. Brock, "Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials, " Cancer Treatment Reviews, vol. 23, no. 1, pp. 35-61, 1997.
22. R. Stupp, P.-Y. Dietrich, S. O. Kraljevic et al., "Promising survival for patients with newly diagnosed glioblastoma multiforme treatedwith concomitant radiation plus temozolomide followed by adjuvant temozolomide, " Journal of Clinical Oncology, vol. 20, no. 5, pp. 1375-1382, 2002.
23. B. Yamini, X. Yu, G. Y. Gillespie, D. W. Kufe, and R. R. Weichselbaum, "Transcriptional targeting of adenovirally delivered tumor necrosis factor αby temozolomide in experimental glioblastoma, " Cancer Research, vol. 64, no. 18, pp. 6381-6384, 2004.
24. R. Stupp, W. P. Mason, M. J. van den Bent et al., "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, " The New England Journal of Medicine, vol. 352, no. 10, pp. 987-996, 2005.
25. W. K. A. Yung, R. E. Albright, J. Olson et al., "A phase II study of temozolemide vs. procarbazine in patients with glioblastoma multiforme at first relapse, " British Journal of Cancer, vol. 83, no. 5, pp. 588-593, 2000.
26. H. Athanassiou, M. Synodinou, E. Maragoudakis et al., "Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme, " Journal of Clinical Oncology, vol. 23, no. 10, pp. 2372-2377, 2005.
27. S. Chibbaro, L. Benvenuti, A. Caprio et al., "Temozolomide as first-line agent in treating high-grade gliomas: phase II study, " Journal of Neuro-Oncology, vol. 67, no. 1-2, pp. 77-81, 2004.
28. L. Cionini, A. Tagliagambe, L. Fatigante et al., "A phase 2 study with concurrent and sequential temozolomide combined with radiation therapy in high grade gliomas, " International Journal of Radiation Oncology Biology Physics, vol. 51, supplement 3, p. S206, 2001.
29. S. E.combs, S. Gutwein, D. Schulz-Ertner et al., "Phase I/IIstudy of temozolomide combined with radiation as postoperative treatment in primary glioblastoma multiforme, " International Journal of Radiation Oncology, Biology, Physics, vol. 60, supplement 1, pp. S258-S259, 2004.
30. G. Lanzetta, C. Campanella, A. Rozzi et al., "Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial, " Anticancer Research, vol. 23, no. 6, pp. 5159-5164, 2003.
31. R. O. Mirimanoff, W. Mason, R. Kortmann et al., "Radiotherapy (RT) and concomitant and adjuvant Temozolomide (TMZ) versus Radiotherapy alone for newly diagnosed glioblastoma (GBM): overall results and Recursive Partitioning Analysis (RPA) of a phase III randomized trial of the EORTC Brain Tumor and Radiotherapy Groups and NCIC Clinical Trial Group, " International Journal of Radiation Oncology, Biology, Physics, vol. 60, supplement 1, p. S162, 2004.
32. W. J. Curran Jr., C. B. Scott, J. Horton et al., "Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials, " Journal of the National Cancer Institute, vol. 85, no. 9, pp. 704-710, 1993.
33. C. B. Scott, C. Scarantino, R. Urtasun et al., "Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06, " International Journal of RadiationOncology Biology Physics, vol. 40, no. 1, pp. 51-55, 1998.
34. D. R. Macdonald, "New frontiers in the treatment of malignant glioma, " Seminars in Oncology, vol. 30, no. 6, pp. 72-76, 2003.
35. C. S. Brock, E. S. Newlands, S. R. Wedge et al., "Phase I trial of temozolomide using an extended continuous oral schedule, " Cancer Research, vol. 58, no. 19, pp. 4363-4367, 1998.
36. F. Baumann, M. Bjeljac, S. S. Kollias et al., "Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme, " Journal of Neuro-Oncology, vol. 67, no. 1-2, pp. 191-200, 2004.
37. M. Carmignani, M. Aldea, O. Soritau et al., "Glioblastoma stem cells: a new target for metformin and arsenic trioxide, " Journal of Biological Regulators and Homeostatic Agents, vol. 2, pp. 1-15, 2014.
38. J. Tuettenberg, R. Grobholz, T. Korn, F. Wenz, R. Erber, and P. Vajkoczy, "Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme, " Journal of Cancer Research and Clinical Oncology, vol. 131, no. 1, pp. 31-40, 2005.
39. M. Bartolomei, C. Mazzetta, D. Handkiewicz-Junak et al., "Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide, " Quarterly Journal of NuclearMedicine andMolecular Imaging, vol. 48, no. 3, pp. 220-228, 2004.
40. R. Ravizza, E. Cereda, E. Monti, and M. B. Gariboldi, "The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells, " International Journal of Oncology, vol. 25, no. 6, pp. 1817-1822, 2004.
41. P. Corsa, S. Parisi, A. Raguso et al., "Temozolomide and radiotherapy as first-line treatment of high-grade gliomas, " Tumori, vol. 92, no. 4, pp. 299-305, 2006.
42. C. A. Barker, A. J. Bishop, M. Chang, K. Beal, and T. A. Chan, "Valproic acid use during radiation therapy for glioblastoma associated with improved survival, " International Journal of Radiation Oncology Biology Physics, vol. 86, no. 3, pp. 504-509, 2013.
43. G. D. Guthrie and S. Eljamel, "Impact of particular antiepileptic drugs on the survival of patients with glioblastomamultiforme, " Journal of Neurosurgery, vol. 118, no. 4, pp. 859-865, 2013.
44. P. Evers, P. P. Lee, J. DeMarco et al., "Irradiation of the potential cancer stem cell niches in the adult brain improves progressionfree survival of patients with malignant glioma, " BMC Cancer, vol. 10, article 384, 2010.
45. H. C. Tsai, K. C. Wei, C. N. Tsai et al., "Effect of valproic acid on the outcome of glioblastoma multiforme, " British Journal of Neurosurgery, vol. 26, no. 3, pp. 347-354, 2012.
46. S. Scoccianti, S. M. Magrini, U. Ricardi et al., "Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the central nervous system study group of Airo (Italian association of radiation oncology), " Neurosurgery, vol. 67, no. 2, pp. 446-458, 2010.
47. T. Iuchi, K. Hatano, T. Kodama et al., "Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma, " International Journal of Radiation Oncology Biology Physics, vol. 88, no. 4, pp. 793-800, 2014.
48. S. Scoccianti, S. M. Magrini, U. Ricardi et al., "Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology), " Neuro-Oncology, vol. 14, no. 6, pp. 798-807, 2012.
49. T. S. Armstrong, J. S. Wefel, M. Wang et al., "Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma, " Journal of Clinical Oncology, vol. 31, no. 32, pp. 4076-4084, 2013.
50. A. Gunjur, M. Bressel, and G. Ryan, "The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy, " Journal of Medical Imaging and Radiation Oncology, vol. 56, no. 5, pp. 567-573, 2012.